EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the Company has entered into a partnership with American HealthCare Lending to provide funding for patient access to vBloc® Therapy, delivered via the Maestro® Rechargeable System, for the treatment of obesity. The Maestro System is approved for adults with a BMI of 40 to 45 kg/m2 or a BMI of 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years.
"American HealthCare Lending is known for providing innovative, affordable and patient-friendly financing options for healthcare-related expenditures," said Brad Hancock, EnteroMedics' Chief Commercial Officer. "This partnership will not only allow broader patient access to vBloc Therapy, but will also be an important resource to physicians in helping their patients gain access to this first-of-its-kind weight loss option."
Exploring AI's role in transforming healthcare diagnosis and treatment